Previous Close | 14.97 |
Open | 15.26 |
Bid | 15.71 x 200 |
Ask | 15.77 x 100 |
Day's Range | 15.10 - 16.05 |
52 Week Range | 4.50 - 30.96 |
Volume | |
Avg. Volume | 842,711 |
Market Cap | 944.109M |
Beta (5Y Monthly) | 1.66 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Immunome (IMNM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IMNM, SLOIF and TMQ have been added to the Zacks Rank #5 (Strong Sell) List on April 4, 2023.
Key Insights Significant control over Immunome by individual investors implies that the general public has more power...